Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Comparison of conventional medicine, TCM treatment, and combination of both conventional medicine and TCM treatment for patients with chronic obstructive pulmonary disease: study protocol of a randomized comparative effectiveness research trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • المؤلفون: Li JS;Li JS; Xie Y; Li SY; Yu XQ
  • المصدر:
    Trials [Trials] 2014 May 01; Vol. 15, pp. 153. Date of Electronic Publication: 2014 May 01.
  • نوع النشر :
    Comparative Study; Journal Article; Multicenter Study; Pragmatic Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • اللغة:
    English
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [London] : BioMed Central, 2006-
    • الموضوع:
    • نبذة مختصرة :
      Background: Chronic obstructive pulmonary disease (COPD) affects millions worldwide. Although many therapies exist and are being developed to relieve symptoms and reduce mortality, few data are available to understand which of the therapeutic alternatives is the most cost-effective for COPD patients in everyday clinical practice, especially for traditional Chinese medicine (TCM). Comparative effectiveness research can help patients, clinicians, and decision-makers make best informed treatment decisions where such evidence was previously lacking. This study aims to compare the effectiveness and economic evaluation of three treatments: (1) conventional Western medicine; (2) TCM treatments, which have been evaluated and have certain effect; and (3) a combination of both conventional Western medicine and TCM treatments, and then determine which treatment is the most suitable for COPD patients.
      Methods/design: A multicenter, pragmatic, randomized, controlled trial is adopted. A total of 360 patients will be recruited and randomly assigned to one of the three treatments group, with 120 in each group. Patients in the conventional Western medicine group will be given Salbutamol, Formoterol, Salmeterol/fluticasone, respectively, according to the guidelines. For the TCM group, patients will be given Bufei granule, Bu-Fei Jian-Pi granule, Bu-Fei Yi-Shen granule, and Yi-Qi Zi-Shen granule based on their corresponding TCM syndrome patterns, respectively. For the combination of conventional medicine and TCM treatments group, patients will be given a combination of conventional Western medicine and TCM granules. Treatments in each group are recognized as a whole comprehensive intervention. After the 26-week treatment, another 26 weeks will be followed up. The outcome measures including the frequency and duration of acute exacerbations, lung function, dyspnea, exercise capacity, quality of life, and economic evaluation will be assessed.
      Discussion: It is hypothesized that each of the three treatments will have beneficial effects in reducing the frequency and duration of acute exacerbations, improving exercise capacity and psychosocial function of COPD patients. In addition, the combination of conventional medicine and TCM treatments may be most suitable for COPD patients with better effectiveness and economic evaluation.
      Trial Registration: ClinicalTrials.gov NCT01836016.
    • References:
      Am J Respir Crit Care Med. 2007 Oct 15;176(8):753-60. (PMID: 17575095)
      JAMA. 2010 Jun 2;303(21):2182-3. (PMID: 20516419)
      Chest. 1988 Mar;93(3):580-6. (PMID: 3342669)
      Clin Trials. 2012 Aug;9(4):436-46. (PMID: 22752634)
      N Engl J Med. 2013 Sep 5;369(10):892-4. (PMID: 23964898)
      J Ethnopharmacol. 2012 Jun 1;141(2):584-91. (PMID: 21911051)
      J Clin Oncol. 2012 Dec 1;30(34):4194-201. (PMID: 23071239)
      BMC Complement Altern Med. 2012 Oct 29;12:197. (PMID: 23107470)
      Eur Respir J. 2009 Sep;34(3):648-54. (PMID: 19720809)
      Am J Respir Crit Care Med. 2013 Feb 1;187(3):320-6. (PMID: 23155144)
      Am J Respir Crit Care Med. 2011 Oct 1;184(7):848-56. (PMID: 21965016)
      JAMA. 2010 Jun 16;303(23):2359-67. (PMID: 20551406)
      J Clin Epidemiol. 2013 Aug;66(8 Suppl):S1-4. (PMID: 23849143)
      Eur Respir Rev. 2009 Dec;18(114):213-21. (PMID: 20956146)
      JAMA. 2010 Jun 16;303(23):2409-10. (PMID: 20551414)
      Lancet. 2008 Oct 25;372(9648):1473-83. (PMID: 18835640)
      Eur Respir J. 2004 Jun;23(6):932-46. (PMID: 15219010)
      Clin Ther. 2013 Apr;35(4):364-70. (PMID: 23477685)
      Pharmacoeconomics. 2012 Apr;30(4):271-302. (PMID: 22409290)
      Chest. 2010 May;137(5):1181-9. (PMID: 20348199)
    • Molecular Sequence:
      ClinicalTrials.gov NCT01836016
    • الرقم المعرف:
      0 (Androstadienes)
      0 (Bronchodilator Agents)
      0 (Drug Combinations)
      0 (Drugs, Chinese Herbal)
      0 (Ethanolamines)
      0 (Fluticasone-Salmeterol Drug Combination)
      QF8SVZ843E (Albuterol)
      W34SHF8J2K (Formoterol Fumarate)
    • الموضوع:
      Date Created: 20140603 Date Completed: 20150219 Latest Revision: 20240506
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC4017822
    • الرقم المعرف:
      10.1186/1745-6215-15-153
    • الرقم المعرف:
      24885672